NK-Cell Clonality by Flow Cytometry: Why KIR-Negative Is Not a Diagnosis

What the study actually establishes

Woodings and colleagues evaluated a 12-colour NK-cell flow cytometry panel in 120 specimens, including peripheral blood, marrow, lymph-node and body fluid samples as well as clinically characterised NK proliferations. To examine expected tissue backgrounds, they analysed 67 specimens without evidence of neoplasia or abnormal NK immunophenotypes: 32 blood, 14 marrow, 11 lymph-node and ten fluid samples. Normal lymph nodes and fluids contained relatively more CD56-bright NK cells than blood or marrow. Because this subset is commonly KIR-negative and CD94/NKG2A-positive, a blood-derived KIR reference range cannot simply be transferred to another specimen. The disease series included EBV-associated NK/T neoplasms, four NK-large granular lymphocytic leukaemia (NK-LGLL) cases and twelve proposed NK clones of uncertain significance (NK-CUS). The study provides context for interpretation; small disease subgroups and observational design prevent a universal diagnostic rule. Source: Woodings et al., Cytometry Part B (2026).

First define the right comparator

NK cells lack the rearranged antigen-receptor system used for B-cell light-chain restriction and T-cell clonality. Their receptor distribution varies with developmental state, immune history and tissue. A KIR-negative fraction therefore is not a self-contained clonality measurement. Before interpreting restriction, document specimen source, sample-processing conditions, NK subset mixture, treatment, transplant history and evidence of ongoing infection or inflammation.

Analyse NK subsets before receptor distributions

Use consistent time, viability and singlet selection, then identify NK-lineage events while avoiding exclusion of unusually high-scatter or marker-altered populations. Stratify CD56-bright and CD56-dim populations, with CD16 and CD57 where appropriate. Interpret the relevant KIRs alongside CD94/NKG2A, marker losses and scatter features. A global NK-cell percentage can shift simply because the CD56-bright fraction changes between specimens. It is safer to report subset-restricted fractions and the parent event counts than one unqualified KIR-negative percentage.

Separate expansion, restriction and malignancy

Three questions require different evidence: whether NK cells are expanded, whether a defined subset has an unusual receptor pattern, and whether the finding supports neoplasia. CMV-associated adaptive NK populations, immune reconstitution and inflammatory settings can restrict the repertoire without demonstrating a malignant clone. In EBV-associated NK/T neoplasms, increased scatter and abnormal antigen patterns may be more useful than KIR negativity alone. The paper also discusses NK-CUS, a proposed entity whose prognostic significance and required surveillance are not fully established.

How to verify clinical transferability

Establish specimen-specific reference distributions and challenge candidate thresholds against diverse normal, reactive and neoplastic populations. Prespecify minimum viable NK events, review low-count uncertainty and examine interobserver gating reproducibility. Titrate antibodies and verify compensation or spectral unmixing, including fluorescence spreading where marker intensities overlap. RUO or analyte-specific reagents in a published laboratory panel do not constitute clearance of an entire clinical method. The local assay still needs method verification or validation matched to its intended use.

Integrate a qualified result

When a restricted NK population is detected, preserve its phenotype, absolute or relative size, confidence limits, and relevant specimen context. Report what is observed rather than converting a single receptor pattern into a disease diagnosis. Longitudinal trends, morphology, cytopenias, clinical behaviour and molecular evidence may refine that interpretation. This is an educational workup framework; it is not a substitute for integrated haematopathologic diagnosis.

Daily Learning Pill — a changing denominator

A rise in global KIR-negative NK cells can occur when the proportion of ordinary CD56-bright cells increases. If subset-specific receptor distributions remain unchanged, the apparent restriction may be compositional rather than new clonality. Analyse the denominator first.

Related CFCM learning and next step

Visit the CFCM clinical flow cytometry library for rare-event interpretation and method validation resources. For the next NK-cell case, record tissue type and CD56-defined subsets before reviewing KIR results.

Evidence and limitations

This is a Technical Review, not a diagnostic guideline. It builds on the paper's Introduction, Methods, Results and Discussion, without reproducing the authors' figures or reanalysing supplementary data. No independent peer review or clinical validation is claimed by CFCM. DOI 10.1002/cyto.b.70078.